Download
1 / 36
0 likes | 11 Views
The hepatotoxicity & drug-induced liver injury testing market size is forecast to reach USD 334.8 million by 2028, after growing at a CAGR of 6.34% during 2023-2028.
E N D
Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC HEPATOTOXICITY AND DILI TESTING MARKET Page - 1 | Web - www.industryarc.com Mail – sales@industryarc.com
Choosing the Right Consulting Partner is Choosing the Choosing the Right Consulting Partner is Choosing the Growth Path OUR EXPERTISE - END TO END CONSULTING Copyright ©2024 IndustryARC IT & Consulting Copyright ©2024 IndustryARC Energy and Power Life sciences and Healthcare Consumer & Retail Electronics Chemicals and Materials Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Topics Slide No Chapter 01: Hepatotoxicity and DILI Testing Market Overview Chapter 01: Hepatotoxicity and DILI Testing Market Overview - 004 Chapter 02: Hepatotoxicity and DILI Testing Market Executive Summary Chapter 02: Hepatotoxicity and DILI Testing Market Executive Summary - 017 Chapter 03: Hepatotoxicity and DILI Testing Market Comparative Analysis Chapter 03: Hepatotoxicity and DILI Testing Market Comparative Analysis - 020 Chapter 04: Hepatotoxicity and DILI Testing Market Forces Chapter 04: Hepatotoxicity and DILI Testing MarketForces - 029 Chapter 05: Hepatotoxicity and DILI Testing Market Strategic Analysis Chapter 05: Hepatotoxicity and DILI Testing Market Strategic Analysis - 039 Chapter 06: Hepatotoxicity and DILI Testing Market - By Xenobiotics Type - 044 Chapter 07: Hepatotoxicity and DILI Testing Market - By Technology - 053 Chapter 08: Hepatotoxicity and DILI Testing Market - By Product Chapter 08: Hepatotoxicity and DILI Testing Market - By Product - 060 Chapter 09: Hepatotoxicity and DILI Testing Market - By End User Chapter 09: Hepatotoxicity and DILI Testing Market - By End User - 067 Chapter 10: Hepatotoxicity and DILI Testing Market - By Geography Chapter 10: Hepatotoxicity and DILI Testing Market - By Geography - 074 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Chapter 11: Hepatotoxicity and DILI Testing Market Company Profiles Chapter 11: Hepatotoxicity and DILI Testing Market Company Profiles - 101 Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 01 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET OVERVIEW Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
❖ The Hepatotoxicity and drug-induced Liver Injury Testing (DILI) testing market refers to the market for tests and technologies used to evaluate the potential liver toxicity of drugs and other chemical compounds. Hepatotoxicity refers to the ability of a substance to cause damage to the liver, while DILI specifically focuses on drug-induced liver injury. ❖ The market for hepatotoxicity and DILI testing is driven by various factors such as the increasing number of drug approvals and the need to ensure drug safety, the rise in drug-induced liver injuries, and the growing emphasis on personalized medicine. Both hepatotoxicity and DILI testing are important to assess the safety of drugs and to identify potential liver toxicity early in the drug development process. ❖ With advances in technology, there is a growing demand for accurate and reliable testing methods to assess hepatotoxicity and DILI during drug development and post-market surveillance. The market is projected to grow due to increasing drug use, regulatory requirements, and advancements in testing technologies. ❖ Different types of tests are used in hepatotoxicity and DILI testing, including biomarker-based assays, in vivo and in vitro models, imaging techniques, and genetic testing. Biomarker-based assays, such as liver function tests and liver-specific biomarkers, are commonly used to evaluate liver health and the presence of toxicity. ❖ In addition to the pharmaceutical industry, the hepatotoxicity and drug-induced liver injury testing market also serves academic research institutions, clinical laboratories, and contract research organizations (CROs) involved in drug Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC development and toxicology. The hepatotoxicity and drug-induced liver injury testing market is projected to witness significant growth in the coming years, driven by increasing drug development activities, rising awareness about drug safety, and the need for more accurate and reliable testing methods to ensure patient safety. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Segment Outlook: ❖ The Hepatotoxicity and Drug-Induced Liver Injury Testing market is divided into categories based on Xenobiotics type, Technology type, Testing products type, End users, and geographical area. By Xenobiotics Type By Technology Type By Testing Product Type By End User By Geography • Drugs • Alcohol • Food additives • Chlorinated solvents • Fungal Toxins • Radioactive isotopes • Environmental toxins • Others • ELISA • Rapid Diagnostic Tests • Polymerase Chain Reaction (PCR) tests • Isothermal Nucleic Acid Amplification Technology (INAAT) tests • Imaging Tests (CT, MRI, Ultrasound etc) • Others • Testing Equipment • Assay Kits • Consumables • Software • Services • Others • Hospitals • Diagnostic Laboratories • Blood Banks • Medical Research Labs • Pharmaceutical Companies • Others • North America • South America • Europe • Asia-pacific Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Research Methodology Flowchart Market Scope & Definition Preliminary Research Data Gathering Data Triangulation Data Synthesis Data Analysis Data Validation Verification Quality Assurance Preliminary Research In the initial stage of research, the scope of the Hepatotoxicity and drug-induced Liver Injury Testing market is defined. In this preliminary stage, the key data points in the market are identified which can be used to estimate the market to the best Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC extent. The scope of this report primarily focuses on the revenue generated from the products manufactured by the major producers. To better gauge the market, the secondary focus is on different layers of the Hepatotoxicity and drug-induced Liver Injury Testing market, such as products catering to disparate segments like applications. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
For this market, the volume of hepatotoxicity and drug-induced liver injury testing, as well as the varying price points, were identified as key informational conjectures for market estimation in 2023. Market performance and trending market dynamics are some of the key questions that are studied during this stage. It also involves studying market factors and changing trends that are projected to affect the market in the future. Data Gathering Based on the scope of the market and the key data points, several secondary sources have been utilized for data gathering. The data gathering stage comprises a team of analysts who gather data by researching secondary research resources, accessing proprietary databases, and with primary research reaching out to key industry participants and opinion leaders (sales & and marketing directors, product managers, market intelligence directors as well as technical experts and administrators) throughout the hepatotoxicity and drug-induced liver injury testing ecosystem including end- use environments forming a crucial aspect of the value chain. The key sources for estimations remained the investments made by end-user verticals along with the sales figures of product suppliers in the market. Also, various trade bodies and associations were taken into consideration to understand the dynamics of each industry vertical and their respective investment scenarios. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Data Synthesis Stakeholders In this stage a team of analysts incorporates the data that has been gathered by corroborating with various sources. These sources include industry participants, In-house Research & Development models, regulatory bodies key opinion leaders in the market ecosystem and databases. In this stage, patterns Hepatotoxicity & Drug-induced Liver Injury Testing Manufacturers in historical data are identified and compared with the current scenario. Based on the macro and micro factors Regulatory Bodies/Testing Authorities prevalent in various geographies, various data models are used to assess the key countries for the market. The Distributors analysis also includes the identification of new companies that have entered the market scenario and End User Segments their impact on the market dynamics in the future. The data regarding end users is gathered from various Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC secondary sources (given towards the end of the presentation). Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Data Analysis After the corroboration of data, the team of analysts moves toward understanding how the market has evolved over the years. The overall market size is gathered after analyzing various segments and verticals of the market. An impact analysis is also carried out to see which factors will affect the market in the next few years. These factors have been researched with respect to prominent economies across different geographic regions to understand their corresponding impact on the market. Verification Data verification is carried out at all stages of research. This stage, however, is dedicated to a more thorough check of all data points, which have been incorporated and rechecked against various data sources. Various C-level executives and key opinion leaders are contacted for verification of the data. The total market for hepatotoxicity and drug-induced liver injury testing is verified through the capital expenditure of various industry verticals. The market is also estimated for various key players in each of the product categories, offering another way of cross-validating the data. The data is then summarized and the key findings are disseminated. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Forecast Methodology Further, time series forecasting methodology is applied based on the various factors such as the product replacement, propensity to buy a new product, average life span, suppliers and distribution margins along with the trade dynamics of the leading countries across the region. Average weighted ASPs are also considered while estimating the market value in the report. The estimates are further revalidated with the suppliers and manufacturers operating in the market. However, some macroeconomic factors like inflation are not considered. Forecasting model is an iterative tool and is backed with historical trends of the market along with a regressive mathematical model which assesses the value based on factors such as capital expenditure, product lifespan, R&D investments and so on. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Assumptions & Research Methodology for Hepatotoxicity & Drug-induced Liver Injury Testing Market Hepatotoxicity & Drug-induced Liver Injury Testing Market Description • Nominal values (i.e. values are not adjusted w.r.t inflation) are considered in the market estimation • The base year is 2022 and 2023 is estimated year. The forecast period is between 2023 and 2028. Historic and Forecast Value Average weighted selling prices of the Hepatotoxicity and drug-induced Liver Injury Testing with respect to their diversified application are considered while arriving on the market in terms of volume. Pricing Average year USD exchange is considered for the estimation of historic values and average five years exchange rate is considered for forecast values. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Exchange Rate Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Assumptions & Research Methodology for Hepatotoxicity & Drug-induced Liver Injury Testing Market S.NO SECONDARY SOURCES 1 MedicinePlus 2 World Gastroenterology Organisation (WGO) 3 The Council for International Organizations of Medical Sciences (CIOMS) 4 National Institutes of Health (NIH) 5 Medscape Education 6 Articles 7 Blogs 8 Annual Reports 9 Investor Presentations Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC 10 White Papers and Journals Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Primary Sources: Hepatotoxicity & Drug-induced Liver Injury Testing Market S.No Designation Company/Organizations 1 Mayo Clinic Business Development Manager 2 Eurofins Sales Manager 3 Syngene International Sales Director 4 Sigma Aldrich Product Marketing Executive Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
HeXa-Grid Paradigm: 6. Data Presentation Data Analysis, Summarization, Key Finding & Reporting is done for efficient dissemination of information 5. Data Triangulation & Validation After data compilation, it is validated with various key opinion leaders and C-level Executives globally 4. Data Interpretation & Assessment Based on the macro and micro factors prevalent in various geographies, proprietary data models are used to assess the key countries for the market 1. Scope Definition: Defining scope of the Report: Analyzing its Services, operations and Geographic penetration Market Assessment Competitive Landscape 2. Secondary Research: Based on the scope and segmentation, secondary research is done using public, private and subscribed sources 3. Primary Research: Reach out to all the stake holders involved in ecosystem: Copyright ©2024 IndustryARC Industry Experts insights taken to gauge and validate key data points Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 02 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET EXECUTIVE SUMMARY Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Global Hepatotoxicity & Drug-induced Liver Injury Testing Market Revenue,2022-2028 ($M) 400 350 300 Revenue ($M) 250 200 150 100 50 0 2022 2023 2024 2025 2026 2027 2028 ❖ The Hepatotoxicity and drug-induced Liver Injury Testing market is estimated to grow at a CAGR of 6.34% during the forecast period (2023-2028) and reach $334.8 million by 2028, from around $231.8 million in 2022. ❖ The hepatotoxicity and DILI testing market is driven by the need to ensure drug safety and the increasing number of drug approvals. Advances in technology and the availability of various test methods are contributing to the growth of this market. The market is projected to witness substantial growth in the coming years, especially in the North American region. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC ❖ The global hepatotoxicity and drug-induced liver injury testing market is projected to grow significantly during the forecast period. Factors driving this growth include the increasing prevalence of liver diseases, rising awareness about drug safety, and the need for more accurate and reliable testing methods. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
❖ Animal Free Research UK (AFRUK) will provide funding, up to a maximum value of £25,000 ($27,003), to toxicology and drug-induced liver injury experts worldwide in 2023 to develop a humanized (non-animal-based) model for toxicity assessment and/or enhance the predictiveness of existing models. Research and testing for drug-induced liver injury, a common side effect of taking medications, are the main focus of AFRUK's Drug-Induced Liver Injury (DILI) Toxicology Innovative Pilot Grants. This type of injury could be avoided by utilizing human-focused techniques that more accurately predict adverse side effects. The objective is to address the problem of inadequate translation from animal-based testing to humans and add to the body of evidence supporting the necessity of using human-centered approaches to investigate medication toxicity. The rising funds and investments is anticipated to drive the market growth. ❖ North America currently dominates the hepatotoxicity and DILI testing market, attributed to factors such as the high prevalence of liver diseases, strong healthcare infrastructure, and substantial investments in research and development. However, the market is also witnessing significant growth in regions such as Asia-Pacific, driven by factors such as increasing healthcare expenditure, rising awareness about liver diseases, and improving healthcare infrastructure. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 04 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET FORCES Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Hepatotoxicity and DILI Testing Market - Drivers Short Term Long Term Medium Term (2025-2026) Drivers (2023-2024) (2027-2028) Increasing demand for herbal and complementary medicines Hepatotoxicity Increased availability of prescription medications Rising Stringent Regulatory Requirements Low High Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Source: IndustryARC Analysis & Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Increasing demand for herbal and complementary medicines Hepatotoxicity ❖ An unusual but potentially deadly type of liver illness is drug-induced liver injury (DILI), which is linked to over-the-counter, prescription, and herbal and dietary supplements (HDS). More people are becoming aware of the possible hepatotoxicity linked to complementary therapies including herbal remedies and nutritional supplements (HDS). ❖ A wide range of liver injuries, including mild asymptomatic liver enzyme elevation, acute and chronic hepatitis, cirrhosis, liver failure, acute and chronic cholangitis, macro- and microvesicular steatosis, and vascular lesions, have been linked to herbal medicines in recent decades. These injuries can affect all cells in the liver and biliary tree. ❖ There are presently few epidemiological investigations of DILI connected to HDS products, according to a 2019 Journal of Hepatology publication. Herbal remedies were placed 9th in terms of DILI frequency in the Spanish DILI registry in 2005, on par with isoniazid. According to the US Drug-Induced Liver Injury Network (DILIN), HDS products are thought to be responsible for 16% of DILI cases overall. This percentage increased from 7% in 2004–2005 to 20% in 2013–2014. This estimate is comparable to the 16% prevalence of HDS-associated hepatotoxicity discovered in an Icelandic prospective study. ❖ Because premarketing clinical trials lack the power to identify idiosyncratic DILI, it is difficult to determine the true prevalence of DILI. On the other hand, the estimated yearly incidence of DILI is 10 to 15 per 10,000 to 100,000 individuals exposed to prescription drugs. As a result, 44,000 or so Americans will contract DILI each year, which is expensive both in terms of the financial toll it takes on individuals as well as medical bills. With the increasing use of HDS, this prevalence is predicted to rise.4. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC 5 More than half of the 2,000 instances of acute liver failure (ALF) that occur in the United States each year are related to medicine; APAP is responsible for 37% of cases, while idiosyncratic adverse drug responses account for 13% of cases. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 05 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET STRATEGIC ANALYSIS Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Hepatotoxicity & Drug-induced Liver Injury Testing , Value Chain Endogenous bile acids Interference with bile canalicular pumps Hepatocyte Injury Hepatotoxic Drugs Lactic Acidosi Necrosis Immune Response Lipid Bile movement, inhibit protein synthesis Apoptotic Pathways Cholestasis Excretory Pathways Damage ❖ Acute or chronic liver injury caused by medicines or herbal chemicals is referred to as drug-induced hepatotoxicity. It is difficult to identify because the symptoms are similar to those of many other hepatobiliary illnesses. The primary treatment is the elimination of the offending agent and strict monitoring for resolution. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC ❖ The serum albumin test measures the level of albumin (a protein in the blood) and aids in the detection of liver disease. The serum alkaline phosphatase test measures the amount of alkaline phosphatase (an enzyme) in the blood. Source IndustryARC Analysis and Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Hepatotoxicity & Drug-induced Liver Injury Testing Market - Opportunity Analysis Short Term (2023-2024) Medium Term (2025-2026) Long Term (2027-2028) Opportunities Using QSAR and toxicogenomic to predict drug-induced hepatotoxicity Low High Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Source: Expert Insights & IndustryARC Analysis Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 08 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET - BY PRODUCT Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
❖ Drug safety evaluations must adhere to strict guidelines set by regulatory bodies like the European Medicines Agency (EMA) and the Testing Equipment: Hepatotoxicity & Drug-induced Liver Injury Testing Market Revenue, 2022-2028 ($M) U.S. Food and Drug Administration (FDA). Comprehensive evaluations of potential liver toxicity are part of this. To comply with these regulations, 45.00 pharmaceutical businesses must invest in testing apparatus. 40.00 ❖ Medical professionals deal with a great deal of problems related to liver 35.00 illnesses, and hepatology's demonstration strategies represent a major 30.00 area for research and development. One important test linked to chronic Revenue ($M) liver disease is the incapacity to identify the illness early. The World 25.00 Health Organization (WHO) estimates that 350 million individuals 20.00 worldwide are continuously afflicted with hepatitis B, one of the many 15.00 diseases that affect the liver. It is anticipated that the market for testing 10.00 equipment would grow as hepatitis B and other liver illnesses become 5.00 more common. ❖ Thorough evaluations of hepatotoxicity can involve the combination of 0.00 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC 2022 2023 2024 2025 2026 2027 2028 multiple testing modalities, such as genetic testing, biomarker analysis, and imaging. Testing apparatus that facilitates multi-modal evaluations makes it possible to comprehend liver toxicity more thoroughly. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
❖ For hepatotoxicity DILI testing, assay kits are available for cell viability, Assay Kits: Hepatotoxicity & Drug-induced Liver Injury Testing Market Revenue, 2022-2028 ($M) apoptosis, oxidative stress, mitochondrial activity, and the identification of certain biomarkers. Due to assay kits being so flexible, researchers 70.00 can select the best kits for the particular studies they are doing. ❖ Regulatory bodies have advocated Assay features for establishing 60.00 toxicity, and the Predictive Safety Testing Consortium (PSTC) has found 50.00 and certified numerous protein biomarkers that may better predict organ-specific toxicity. Moreover, it is ideal for toxicity biomarkers to be Revenue ($M) 40.00 applicable to preclinical models where early safety is regularly 30.00 evaluated. ❖ A precise, multiparametric investigation of toxicity and its underlying 20.00 mechanisms is made possible by bead-based multiplex toxicity tests. Researchers may simultaneously measure dozens of toxicity analytes 10.00 across various species with the use of Sigma Aldrich MILLIPLEX® 0.00 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC multiplex toxicity biomarker test kits. These assays, for instance, can 2022 2023 2024 2025 2026 2027 2028 examine particular toxicities such as medication-induced hepatitis. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 09 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET - BY END USER Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
❖ Healthcare practitioners are becoming more aware of the possibility of drug- Hospitals: Hepatotoxicity & Drug-induced Liver Injury Testing Market Revenue, 2022-2028 ($M) induced liver injury. As part of continuing education and training, hospitals are progressively integrating hepatotoxicity testing into their protocols. 100.00 90.00 Personalized medicine is becoming more and more popular in hospitals, 80.00 where drug selection and dosage are determined by specific patient 70.00 variables. Through the assessment of patient-specific hazards, Revenue ($M) 60.00 hepatotoxicity testing advances customized therapy. ❖ An analysis of national hospitalization data indicates that a spike in hospital 50.00 40.00 admissions for alcohol-related hepatitis, a potentially fatal liver 30.00 inflammation, coincided with a surge in alcohol sales during the epidemic, 20.00 potentially having disastrous effects on many. ❖ Additionally, Researchers discovered a spike in cases of alcohol-related liver 10.00 0.00 2022 2023 2024 2025 2026 2027 2028 disease from 2016 to 2020; however, the increase was most noticeable in 2020, the year COVID-19 entered the United States, with a 12.4% increase over 2019 levels. For patients between the ages of 18 and 44, hospital admissions for hepatitis connected to alcohol increased by over 20%, and in this group, the situation was worse. In 2020, there was a 24.6% rise in in- Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC hospital fatalities compared to 2019. This meant that the repercussions were even worse. As a result, the market is growing for hepatotoxicity & drug-induced liver injury testing. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
❖ Comprehensive testing services are made possible in large part by diagnostic Diagnostic Laboratories: Hepatotoxicity & Drug- induced Liver Injury Testing Market Revenue, 2022-2028 ($M) laboratories. Specialized testing to evaluate possible hepatotoxicity and drug- induced liver disease is becoming more and more necessary as the 160.00 pharmaceutical industry develops new medications. The accuracy and 140.00 sensitivity of hepatotoxicity testing are improved by the use of cutting-edge technology in diagnostic laboratories, such as mass spectrometry, molecular 120.00 diagnostics, and imaging modalities. This draws in more customers looking for 100.00 Revenue ($M) cutting-edge services. ❖ A research study titled "Effect of Increased Alcohol Consumption During 80.00 60.00 COVID-19 Pandemic on Alcohol-Associated Liver Disease: A Modeling Study" 40.00 published in December 2021 states that by 2040, an increase in alcohol 20.00 consumption could result in 8,000 more deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer. As a 0.00 2022 2023 2024 2025 2026 2027 2028 result, there will likely be a greater need for sophisticated and efficient diagnostic tools to ensure that patients receive the proper care. ❖ On 24 January 2023, A major new study spearheaded by WHO and conducted in partnership with the University of Bristol was published in Lancet Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Gastroenterology and Hepatology. It demonstrated the advantages of a rapid diagnostic test for hepatitis C virus (HCV) infection conducted in a clinic over a traditional laboratory-based test. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 10 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET - BY GEOGRAPHY Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
❖ One of the leading causes of DILI in China is Chinese herbal medicine. China: Hepatotoxicity & Drug-induced Liver Injury Testing Market Revenue, 2022 - 2028 ($M) According to a 2021 study titled Current Advances in Resource Utilisation of Herbal Extraction Residues in China, there are over 1500 medicinal herb 25.00 companies in China, with an annual yield of up to 35 million tonnes of Chinese herb-extracted residues (CHERs). ❖ Alcohol-associated hepatitis has been a common precipitant of Acute-on- 20.00 chronic liver failure (ACLF), especially during the COVID-19 era. Reactivation Revenue ($M) 15.00 of chronic hepatitis B is a leading precipitating factor for ACLF in China. For instance, in a 2018 study, the incidence rate according to APASL (Asian- 10.00 Pacific Association for the Study of the Liver)-ACLF criteria was 5.7 per 1,000 persons, and the global prevalence was 35%, with a higher prevalence in 5.00 South Asia (65%). ❖ According to data from the China Centre for Disease Control and Prevention 0.00 Information Centre 2023, liver cancer is the fifth most prevalent malignant 2022 2023 2024 2025 2026 2027 2028 tumour in China and the second major cause of cancer death. The majority of liver cancer patients in China have hepatitis B virus infection/a history of cirrhosis, and the majority of them are intermediate or advanced (70%) at Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC the time of presentation. The hepatotoxicity & drug-induced liver Injury testing market is expanding in response to the growing need for early detection of liver cancer, which is critical for improving patient survival rates. Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 11 HEPATOTOXICITY AND DRUG-INDUCED LIVER INJURY TESTING MARKET - COMPANY PROFILES Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Eurofins Scientific: Product Portfolio Business Overview Product /service Description Eurofins Scientific Description It detects unwanted adverse liver effects with specially designed assays. Rapid compound profiling with a high-throughput screening panel, In-depth assessment for DILI potential with detailed mechanistic assays Established Year 1987 In vitro cell- based toxicity assays Headquarters Luxembourg Revenue (2022) $7,068.1 Employees (2022) 61,000 Website https://www.eurofins.com/ Financials: Eurofins Scientific, 2020-2022 ($M) Eurofins Scientific, Revenue Share, By Segment, 2022 (%) Eurofins Scientific, Revenue Share, By Geography, 2022 (%) 9,000 7,945.3 Sample-based business 0% 6%2% 8,000 7,068.1 9% 11% 7,000 6,212.2 Study-based business 6,000 Revenue($M) Europe 5,000 FTE-based business 4,000 North America 3,000 52% Product-based business 2,000 37% 83% Rest of the World 1,000 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Other 0 2020 2021 2022 Developments: There are no developments for the last 5 years pertaining to the market Source: Company News and Press Releases Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Thank You! IndustryARC +1 614-588-8537/38 sales@IndustryARC.com Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Page - 36 | Web - www.industryarc.com Mail – sales@industryarc.com
